CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells. [PDF]
PLoS ONEGemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh +6 more
doaj +2 more sources
Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy
Asian Journal of Pharmaceutical Sciences, 2022 Gemcitabine has been extensively applied in treating various solid tumors. Nonetheless, the clinical performance of gemcitabine is severely restricted by its unsatisfactory pharmacokinetic parameters and easy deactivation mainly because of its rapid ...
Haijie Han +7 more
doaj +1 more source
Study of the Efficacy and Multidrug Resistance Using Gold Nanoparticles-Based Drug Delivery Versus Conventional Chemotherapy in Non-Small-Cell Lung Cancer Cell Line [PDF]
Research in Oncology, 2021 Background: Cisplatin is the main chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) combined with gemcitabine or other agents. Aim: The aim of this study was to evaluate in vitro the anti-tumor efficacy and multidrug resistance of gold
Aida A. Guemei +4 more
doaj +1 more source
The synthesis of gemcitabine [PDF]
Carbohydrate Research, 2014 Gemcitabine is a fluorinated nucleoside currently administered against a number of cancers. It consists of a cytosine base and a 2-deoxy-2,2-difluororibose sugar. The synthetic challenges associated with the introduction of the fluorine atoms, as well as with nucleobase introduction of 2,2-difluorinated sugars, combined with the requirement to have an ...
Brown, Kylie +3 more
openaire +4 more sources
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD. [PDF]
PLoS ONE, 2015 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75-80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve
Qing Zhang +5 more
doaj +1 more source
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. [PDF]
, 2016 First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.
Barile, Elisa +11 more
core +5 more sources
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. [PDF]
PLoS ONE, 2012 Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su ...
Niranjan Awasthi +4 more
doaj +1 more source
Pharmaceuticals, 2022 Gemcitabine is a chemotherapeutic used clinically to treat a variety of cancers. However, because it lacks tumor cell specificity, gemcitabine may cause off-target cytotoxicity and adversely impact patients.
Jianjun Qi +8 more
doaj +1 more source
Activity of combined gemcitabine therapy on treatment of planocellular carcinoma: A pilot study [PDF]
Archive of Oncology, 2004 BACKGROUND: Drug-orientated, pilot study was conducted to estimate the activity of gemcitabine on treatment of head and neck and lung planocellular carcinoma in combination with either radiotherapy or chemotherapy.
Šćepanović Danijela S. +2 more
doaj +1 more source
Clinical and Translational Science, 2020 This study intends to compare short‐term efficacy of 12 chemotherapy regimens in treatment of advanced non‐small cell lung cancer (NSCLC) by a network meta‐analysis (NMA).
Bei‐Bei Zhang +6 more
doaj +1 more source